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Background: Dendritic cells (DC) are localized in close proximity to cancer cells in many
well-known tumors, and thus maybe a useful target for tumor margin assessment.
Materials and methods: [99mTc]- cyanine 7 (Cy7)-tilmanocept was synthesized and in vitro
binding assays to bone marrow-derived DC were performed. Fifteen mice, implanted with
either 4T1 mouse mammary or K1735 mouse melanoma tumors, were administered
1.0 nmol of [99mTc]-Cy7-tilmanocept via tail vein injection. After fluorescence imaging 1 or
2 h after injection, the tumor, muscle, and blood were assayed for radioactivity to calculate
percent-injected dose. Digital images of the tumors after immunohistochemical staining
for DC were analyzed to determine DC density.
Results: In vitro binding demonstrated subnanomolar affinity of [99mTc]-Cy7-tilmanocept to
DC (KA ¼ 0.31  0.11 nM). After administration of [99mTc]-Cy7-tilmanocept, fluorescence
imaging showed a 5.5-fold increase in tumor signal as compared with preinjection images
and a 3.3-fold difference in fluorescence activity when comparing the tumor with the
surgical bed after tumor excision. Immunohistochemical staining analysis demonstrated
that DC density positively correlated with tumor percent of injected dose per gram
(r ¼ 0.672, P ¼ 0.03), and higher DC density was observed at the periphery versus center of
the tumor (186  54 K versus 64  16 K arbitrary units, P ¼ 0.001).
Conclusions: [99mTc]-Cy7-tilmanocept exhibits in vitro and in vivo tumor-specific binding to
DC and maybe useful as a tumor margin targeting agent.
ª 2014 The Authors. Published by Elsevier Inc. All rights reserved.CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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j o u r n a l o f s u r g i c a l r e s e a r c h 1 9 0 ( 2 0 1 4 ) 5 2 8e5 3 4 5291. Introduction Beckman Coulter, Inc, Brea, CA) using 0.9% saline as the mo-Dendritic cells (DC) play a critical role in immunity through
capturing and processing antigens, migrating to lymphoid
organs, and activating T and B lymphocytes [1]. Through this
same process, they promote antineoplastic activity; studies
have shown that higher numbers of tumor-infiltrating den-
dritic cells (TIDC) correlate with improved prognosis [1,2].
Some human tumors, such as breast cancer, have a consid-
erable amount of TIDC [3,4], whereas other tumors such as
renal cell carcinoma have poor infiltration [5]. Similarly, mu-
rine models have shown varying amounts of TIDC depending
on tumor type, with the mammary 4T1 [6] and the melanoma
K1735 [7] murine tumor models showing numerous TIDC.
Due to the propensity of DC to infiltrate breast cancer, TIDC
maybe a useful marker for determining tumor margins intra-
operatively. Mature DC found specifically along the tumor pe-
riphery inhumanbreastcancer further supports theuseofTIDC
as a potential tumormargin target [8]. Assessing tumormargins
in the operating room in modern breast surgery is suboptimal,
with frozen section analysis of margins resulting in a
re-excision rate around 20% [9,10]. Positive margins are associ-
ated with higher cancer recurrence rates after breast conser-
vation therapy [11], and therefore more accurate methods of
identifying tumor margins intraoperatively are needed. One
such approachmay be to target TIDC owing to their infiltration
of and peripheral distribution within breast tumors.
Tilmanocept, also known as diethylenetriaminepenta-
acetic acid-mannosyl-dextran and Lymphoseek (Navidea
Biopharmaceuticals, Dublin, OH), is a radiopharmaceutical
that exhibits specific binding to mannose-binding protein re-
ceptor present on some immune cells derived from the
mononuclear phagocytic lineage, from which DC arise. It is a
synthetic molecule composed of a dextran backbone with
multiple mannose units that serve as receptor recognition
sites and diethylenetriaminepentaacetic acid units that can be
labeled for molecular detection [12,13].
Our group has previously published subnanomolar binding
affinity of tilmanocept to macrophages, but the binding po-
tential to DC has not been studied. The purpose of this study is
to determine the in vitro and in vivo binding capacity of [99mTc]-
cyanine 7 (Cy7)-tilmanocept to DC using nuclear and fluores-
cence detection and to determine its utility in tumor margin
analysis.
2. Materials and methods
Tilmanocept was provided by Navidea Biopharmaceuticals.
The authors of this study had full control over the inclusion of
all data and information submitted for publication. This study
was approved by the Institutional Animal Care and Use
Committee of the University of California, San Diego.
2.1. Fluorescence- and radio-labeling of tilmanocept
The conjugation of Cy7 to the dextran backbone of tilmano-
cept was performed in a manner previously described [14,15].
Purity was confirmed by size exclusion (TSKgel G2000SWx1;
Tosoh Bioscience LLC, Tokyo, Japan) HPLC (System Gold;bile phase [16]. The eluate was monitored by UV absorbance
and fluorescence (L-7480; Hitachi America, Ltd, Farmington
Hills, MI). The fluorescence purity of all preparations was in
excess of 98%. Estimation of Cy7 density was defined as the
average number of Cy7 molecules per tilmanocept molecule
[15]. The resultant density was two molecules of Cy7 per til-
manocept molecule. Radiolabeling of Cy7-tilmanocept was
performed using a tin reduction method [15]. Figure 1 shows
the structure of [99mTc]-Cy7-tilmanocept.
2.2. [99mTc]-cy7-tilmanocept in vitro binding assays
C57BL/6 bone marrow-derived dendritic cells (BMDC) were pre-
pared as described previously [17]. One hundred twenty million
immature BMDCwere separated into five vials of 24million cells
each. The final concentration was 4.8million cells per 0.1 mL of
solution, and the final ligand concentrations were 0.0625, 0.125,
0.375, 0.75, and 15 nmol/L. Each ligand-cell mixture was vor-
texed, incubated on ice for 1 h, and vortexed again. Next, four
tubes for every ligand concentration were made by combining
0.1 mL of ligand-cell mixture with 0.15 mL of a 4:1 mixture of
silicon fluid 550 and mineral oil. Tubes were centrifuged
(Microfuge E; BeckmanCoulter, Inc) for 30 s. The bound fraction,
assumed to be within the cell pellet, was separated from the
free fraction by cutting through the oil layer and assayed sepa-
rately for gamma radiation (Gamma 9000; Beckman Coulter,
Inc). Each stock ligand concentration had 0.05 mL taken for a
standard measurement. The equilibrium disassociation con-
stant (KD) was estimated using LIGAND software [18] (National
Institutes of Health, Bethesda, MD) and the resulting regression
presented as a Scatchard plot [19]. This protocol was performed
at 4C to eliminate the effect of receptor recycling. The mean
and standarddeviationof triplicatemeasurements are reported.
2.3. 4T1 cell culture and tumor implantation
Ten 6-wk-old female BALB/c mice and five 6-wk-old female
B6C3F1 (weight range 18e27 g) were purchased from Charles
River Laboratories (Wilmington, MA). All the mice were of the
same gender to minimize any variables that could potentially
influence results. The mice were given a week long acclimation
period before tumor implantation. The 4T1 cell line originated
from a female BALB/c mouse mammary tumor and was gifted
from the Stupack Laboratory [20]. The K1735 cell line originated
from an inbred C3H/HeNmurinemelanoma tumor [21] andwas
gifted from Professor B. Werhle-Haller (Geneva University Medi-
cal Center, Geneva, Switzerland). Cells were grown in Dulbecco
ModifiedEagleMediumsolutionwith 10% fetal bovine serum.On
thedayoftumorimplantation, the4T1tumorcellsuspensionand
the K1735 tumor cell suspension were prepared to a concentra-
tion of 8 million cells/mL and 2.4 million cells/mL, respectively.
Each suspension (0.25mL) was drawn up into 1mL syringes and
placed on ice. All mice were anesthetized by inhalation of 2%
isoflurane. Under anesthesia, one hind leg of each mouse was
shaved and cleaned with alcohol, and 0.25mL cell suspension (2
million4T1 tumorcellsor600,000K1735 tumorcells)was injected
subcutaneously in this region. Tumorswere grown over a period
of 14 d for the 4T1 cell line and 20 d for the K1735 cell line.
Fig. 1 e [99mTc]-Cy7-tilmanocept with technetium-99m (red), Cy7 (blue), and mannose-binding receptor (green).
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All mice were deemed ready for [99mTc]-Cy7-tilmanocept in-
jection based on tumor size (volume range 60e609 mm3).
Under anesthesia, each mouse underwent tail vein injection
of 1.0 nmol (0.1 mL, 250 mCi) of [99mTc]-Cy7-tilmanocept. Each
mousewas imaged using a 758 nmexcitation laser and 782 nm
emission detection (Optix MX2 Advanced Research Technol-
ogies, Montreal, Canada) before injection and at 1 or 2 h after
injection. Five of the 4T1-bearingmice were imaged at 1 h and
five at 2 h. The K1735-bearing mice were imaged at 1 h. Ani-
mals were euthanized after fluorescence images were ob-
tained. The B6C3F1 mice underwent additional fluorescence
imaging of the surgical bed alongside the excised tumor and
excised muscle from the opposite hind leg. The fluorescence
images were viewed using standard software (Optiview;
Advanced Research Technologies, Montreal, Canada) andFig. 2 e The Scatchard plot shows results of a single in vitro
binding experiment analyzed with LIGAND software [18],
which separates the specific-(:) and nonspecific-bound
(6) radioactivity before estimation of a KD. Inset shows
expanded view of the specific-bound component used to
calculate the KD, which was 0.19 ± 0.19 nM (negative slope
of straight solid line). Mean KD of the three in vitro binding
assays was 0.31 ± 0.11 nM.analyzed by drawing a circular region of interest around each
tumor to determine maximum fluorescence count. Each re-
gion of interest encircled a 1  1 mm2 pixel area.
2.5. Ex vivo nuclear counts and calculation of % ID per
gram
Tumor, blood, and muscle from the hind leg opposite the
tumor were removed and placed in separate plastic scintilla-
tion vials. Radioactivity was assayed for each of these three
entities for each animal with a gamma counter using a
100e200 keV window (Gamma 9000; Beckman Coulter, Inc).
Each sample was compared with a counting standard pre-
pared from a known dilution of [99mTc]-Cy7-tilmanocept. The
amount of [99mTc]-Cy7-tilmanocept within each scintillation
vial was expressed as percentage of injected dose of [99mTc]-
Cy7-tilmanocept per gram of tissue, which was calculated by
comparing the radioactivity in each vial with the radioactivity
in the counting standard.
2.6. Pathology and immunohistochemical analysis
After radioactivity counts were obtained, the tumor from each
mousewassubmitted topathologyas frozenblocksembedded in
Optimal Cutting Temperate compound (Sakura, Torrance, CA).
Tumors were stained for DC using DC-specific integrin Cd11c
antibody [22] purchased from BD Biosciences-Pharmingen (San
Jose,CA) .Digital imageswere takenofeach4T1tumorsliceusing
20 objective on the light microscope and SPOT basic software
(Version 4.7, SPOT Imaging Solutions, Sterling Heights, MI). Im-
ages were taken both at the center of the tumor tissue and the
periphery. Each image was analyzed using the magic wand
method as described in other studies [23] to determine the den-
sity of DC expressed as the immunocytochemical (ICC) index in
arbitrary units.
2.7. Statistical analysis
The Student two-tailed t-test and the Wilcoxon test (JMP;
version 9, 2010; SAS Institute, Cary, NC) were used to compare
the percent of injected dose per gram (%ID/g) of tumor versus
Fig. 3 e Fluorescence images of a BALB/c mouse with a 4T1 tumor acquired 1 h after injection show increased peak intensity
(kc sL1 mWL1) from before injection (A) to after injection (B) of tail vein injection of 1.0 nmol [99mTc]-Cy7-tilmanocept.
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P value of <0.05 was considered significant. The Pearson cor-
relation coefficient was used to determine the correlation of %
ID/g of tumor to the ICC index of each tumor using the average
of the central and peripheral tumor ICC indices for each
specimen.Fig. 4 e After excision of the K1735 tumor in a B6C3F1
mouse, peak fluorescence activity in the surgical bed is
29.4 kc$sL1$mWL1. Similarly, muscle (M) excised from the
opposite hind leg has 30.7 kc$sL1$mWL1 peak fluorescence
activity versus 119.7 kc$sL1$mWL1 in the tumor (T). The
mouse was euthanized 1 h after injection of fluorescent-
labeled tilmanocept.3. Results
3.1. Subnanomolar binding affinity to DC
Figure 2 displays a representative Scatchard plot [19]. The
mean KD for this experiment was 0.19  0.19 nM. Three
binding assays yielded a mean KD of 0.31  0.11 nM.
3.2. Fluorescence imaging and percentage of injected
dose shows tumor uptake of [99mTc]-Cy7-tilmanocept
Figure 3 shows representative fluorescence images of a BALB/c
mouse with increased peak activity from before injection to
after injection of [99mTc]-Cy7-tilmanocept. In Figure 4, fluo-
rescence activity is shown after removal of the tumor in a
representative B6C3F1 mouse, with little fluorescence in the
surgical bed or the muscle excised from the opposite hind leg
as comparedwith high peak activity in the excised tumor. The
peak fluorescence values for the tumor, muscle, and surgical
bed for this mouse are 119.7, 30.7, and 29.4 kc$s1$mW1,
respectively. The peak fluorescence activity is 4.1 times
greater in the tumor than the surgical bed in this example, and
for the five B6C3F1mice undergoing ex vivo tumor imaging, the
mean ratio of tumor to surgical bed peak fluorescence activity
is 3.3  2.0 kc$s1$mW1.
The %ID/g measurements demonstrated increased
amounts of [99mTc]-Cy7-tilmanocept in tumor tissue as well.
4T1 tumors imaged at 1 h showed 1.76  0.36%ID/g versus
0.40  0.20%ID/g in muscle excised from the opposite hind leg
(P < 0.001) and 6.7  6.4%ID/g in the blood. The five 4T1-
bearing mice euthanized at 2 h after injection exhibited
1.06  0.25%ID/g in the tumor versus 0.22  0.13%ID/g inmuscle (P < 0.001) and1.33  0.17%ID/g in the blood. The
K1735-bearing mice had 1.09  0.21%ID/g in the tumors versus
0.27  0.08%ID/g in muscle (P < 0.001). Blood contained
2.08  0.91%ID/g.
3.3. Immunohistochemistry shows increased DC density
at tumor margins and a positive correlation between DC
density and %ID/g
Figure 5 shows CD11c staining of 4T1 tumor tissue to identify
DC. Density of DC was found to be greater in the tumor pe-
riphery versus the center (186  54 K versus 64  16 K arbitrary
units, P ¼ 0.001). DC density also positively correlated with
%ID/g with a r2 of 0.61 (Fig. 6).
4. Discussion
The purpose of this study was to determine the binding af-
finity of [99mTc]-Cy7-tilmanocept to DC and to determine the
intratumoral binding of our probe in amouse tumormodel. In
our in vitro studies, we found subnanomolar binding affinity of
tilmanocept to BMDC, signifying avid binding. Prior studies
have investigated the receptor-binding capacity of our probe
Fig. 5 e CD11c staining of DC (arrows) within 4T1 tumor tissue in red. (A) Central tumor shows less DC density than (B)
tumor periphery (15,521 versus 162,618 arbitrary units). Standard hematoxylin and eosin staining of central tumor (C) and
peripheral tumor (D) is shown for comparison.
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similar subnanomolar binding was observed [15]. However,
this is the first study to report DC binding affinity. Like mac-
rophages, DC are known to express mannose-binding protein
and this likely explains the observed specific binding.
To evaluate in vivo intratumoral binding characteristics,
both fluorescence and radioactive labeling were used to
measure tumor uptake of our probe after intravenous injec-
tion. Fluorescence imaging studies showed a 5.5-fold increase
in tumor signal when comparing before and after injection
images, indicating localization of our probe. Additionally,
after tumor excision, there was 3.3-fold greater peakFig. 6 e Density of DC based on immunocytochemical
index analysis shows a positive correlation with [99mTc]-
Cy7-tilmanocept tumor accumulation (r[ 0.61, P[ 0.004).fluorescence activity in the tumor as compared with the sur-
gical bed. Similarly, ex vivo nuclear counts showed uptake of
the probe by the tumor with a significant 4.5-fold greater
amount of injected dose present in the tumor when compared
with muscle from the opposite hind leg, signifying tumor-
specific uptake of the radiopharmaceutical.
On pathology, DC density positively correlated with percent
of injected dose. These results further corroborate the binding
of [99mTc]-Cy7-tilmanocept to TIDC. Given that we found TIDC
to be significantlymore concentrated at the periphery of tumor
sections as comparedwith the center, [99mTc]-Cy7-tilmanocept
maybe valuable as a probe in tumor margin analysis.
Onemajor limitation of this study is the small sample size,
and further experiments should be conducted with larger
sample sizes to corroborate this data. The small sample size is
especially evident in the K1735 tumor group with five mice,
giving a large standard deviation when comparing peak fluo-
rescence activity of the excised tumor with that of the surgical
bed. One mouse in this group was an outlier with high fluo-
rescence activity in the surgical bed and in the excised tumor,
possibly signifying tumor tissue left behind. The other four
mice, however, all had at least 3-fold higher peak fluorescence
activity in the tumor as compared with the surgical bed. In
future experiments, histochemical analysis of tumor margins
should also be performed to compare with imaging data.
Overall, however, this pilot study shows that [99mTc]-Cy7-
tilmanocept binds to DC found in higher concentrations at
the tumor periphery, and therefore its potential as tumor
margin targeting agent should be further explored.
This application of [99mTc]-Cy7-tilmanocept would be
especially useful in managing breast cancer in the operating
j o u r n a l o f s u r g i c a l r e s e a r c h 1 9 0 ( 2 0 1 4 ) 5 2 8e5 3 4 533room. Breast conservation therapy has become the treatment
standard for most breast tumors. However, it has limitations:
it is difficult to assess tumormargins in the operating room as
evidenced by the 20%e40% positive margin rate [24] and
additional surgery is necessary if residual tumor is left behind.
To avoid this high re-excision rate, improved techniques of
intraoperative breast tumor margin assessment are needed.
Molecular imaging technologies are increasingly being used to
analyze cancers, with rapid growth in the field of in vivo
fluorescence imaging [25]. Near-infrared (NIR) fluorescence
dyes like Cy7 have high tissue penetration and low auto-
fluorescence, making them ideal for use in the operating room
[26]. Advances in fluorescence imaging have already been
applied to intraoperative tumor detection in other areas of
oncology [27]. Specifically, clinical trials have shown prom-
ising results using fluorescence imaging in the detection of
both primary liver lesions [28] and colorectal metastases to
the liver [29]. Fluorescence imaging has also been applied to
parathyroid adenoma identification with positive outcomes
[30].
Although fluorescence imaging has not yet been used for
human breast cancer management outside of sentinel node
mapping, in vivo studies in the rat model have been effective in
detecting tumor margins with intraoperative NIR fluorescence
imaging systems [31]. Similar methods can be applied to
intraoperative human breast cancer tumor analysis using Cy7-
tilmanocept. After intravenous injection of Cy7-tilmanocept up
to 24 h before surgery, handheld intraoperative NIR fluores-
cence imaging systems can be used to demarcate the margins
of the tumor. After tumor excision, the optical system can also
be used to evaluate the surgical bed for any remaining fluo-
rescence activity potentially could signify residual tumor.
BeforeTIDCcanbeused for tumormargindetection inbreast
cancer, further research should be directed toward better un-
derstanding their role in the tumor environment. For example,
there is great variability in the number of TIDC from one breast
cancer patient to the next [32]. Iwamoto et al. [33] showed that
increased amounts of certain types of TIDC are associatedwith
earlier stage breast cancers. Targeting this subtype of TIDC for
margin identification may prove beneficial, because patients
with early stage cancer are candidates for breast conservation
therapy; therefore, these patients would most benefit from
[99mTc]-Cy7-tilmanocept as a margin targeting agent. Those
patients with more advanced cancer are more likely to require
mastectomy without the need for intraoperative margin anal-
ysis. Another way to overcome the variability in the number of
TIDC is to develop methods to increase the number of TIDC in
the tumor, such as through high-intensity focused ultrasound
[8]. Finally, the increased number of DC in other inflammatory
conditions, such as autoimmune diseases, poses another po-
tential limitation in using TIDC to identify tumor margins.
Further research should focus on determining if these states
interfere with [99mTc]-Cy7-tilmanocept TIDC binding.Acknowledgment
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